Colgate-Palmolive India Q1 FY26: Targets Cut

Colgate-Palmolive (India) Ltd. drew a cautious response from brokerages after its Q1 FY26 performance showed weaker growth, with the company pointing to subdued urban demand and elevated competitive intensity. While management reiterated its focus on premiumisation and brand investment, several analysts reduced target prices and trimmed earnings expectations, citing muted near-term momentum.

Alongside Q1 commentary, the company also disclosed a Q2 FY26 sales and profit print and announced an interim dividend. In parallel, Colgate-Palmolive’s global Q1 earnings call highlighted cost inflation pressures, pricing and productivity levers, and the importance of Asia Pacific and innovation, which remain relevant for investor context even as India’s near-term demand remains uneven.

Q1 FY26 financial snapshot for Colgate-Palmolive (India)

For the quarter ended June 2025 (Q1 FY26), Colgate-Palmolive (India) reported a 12% year-on-year decline in net profit to ₹320.62 crore, compared with ₹363.98 crore in Q1 FY25. Revenue from operations fell 4.4% year-on-year to ₹1,420.64 crore from ₹1,485.76 crore.

Sequentially, profit declined from ₹355 crore in Q4 FY25, while revenue from operations decreased 2.16% from ₹1,452.02 crore in Q4 FY25. Total expenses in Q1 FY26 stood at ₹1,020.05 crore, marginally lower than ₹1,030.86 crore a year ago, but higher than ₹1,003.95 crore in the previous quarter.

The company’s earnings per share (basic and diluted) for the quarter was ₹11.79. The period was also characterised by demand divergence, with management commentary in the broader disclosure highlighting pressure in urban markets.

What the company said drove the quarter

Colgate-Palmolive (India) attributed the softer quarter to “subdued urban demand and elevated competition intensity.” It also said the quarter was affected by cycling a higher base, noting that net sales grew at a 12% CAGR in the base-year comparison period (Q1 FY23 to Q1 FY25).

The pressure points in the operating environment were not framed as a single event but as a combination of slower discretionary momentum in cities and higher competitive activity. That backdrop matters for oral care, where promotional intensity and pricing architecture can quickly influence volume and market share trends.

Management view: premiumisation and brand investment

Managing Director and CEO Prabha Narasimhan said the company continued executing its strategic priorities during the quarter. She highlighted progress in category premiumisation, with the premium portfolio delivering strong revenue growth.

She also pointed to continued brand investment, supported by healthy profit margins. The company said it expects to navigate the current challenges and anticipates a gradual recovery in the back half of the year, positioning H2 as a more supportive period relative to a difficult first half.

Brokerages turn cautious after Q1 FY26

Following Q1 FY26 results, multiple brokerages adopted a guarded stance on the near-term outlook and reduced target prices. JPMorgan maintained an “Overweight” rating but cut its target price to ₹2,625 from ₹2,750, citing a tough first half and a back-ended recovery thesis.

JPMorgan flagged that higher trade promotions contributed to muted price growth in Q1, and it expects a return to positive price growth in H2 on stability in competition, anniversarisation of prior promotions, and faster growth in premium segments. It also said EBITDA margins should hold at 32-33% and reduced FY26-27 EPS estimates by 6% due to lower revenue forecasts.

HSBC maintained a “Hold” rating and reduced its target to ₹2,600 from ₹2,700, flagging a tepid growth outlook. Goldman Sachs maintained a “Sell” with a target price of ₹2,300 and highlighted a 4% revenue decline and an 11% fall in EBITDA year-on-year. Citi retained a “Sell” and cut its target to ₹2,175 from ₹2,300.

Nuvama was the outlier on positioning, maintaining a “Buy” with a target price of ₹3,135. It acknowledged softness in Q1 revenue and EBITDA, attributing it to weak urban demand and a high base, and also noted toothpaste volumes declined 2% year-on-year against a strong base of 8-9%.

Street positioning: Buy, Hold, Sell split

Bloomberg data in the disclosure showed a divided analyst community. Out of 34 analysts tracking the stock, 10 rated it “Buy”, 12 suggested “Hold”, and 12 recommended “Sell”.

The split reflects a market that is weighing near-term volume and pricing pressures against the brand’s long-term positioning and the possibility of a back-half recovery, as described by management and at least one large brokerage.

Q2 FY26 update and interim dividend

Colgate-Palmolive (India) also announced Q2 FY26 results with net sales of ₹1,507 crore, compared with ₹1,609 crore in Q2 FY25. Against ₹1,421 crore in Q1 FY26, the company reported sequential net sales growth of 6.1%.

Net profit after tax for Q2 FY26 stood at ₹328 crore, compared with ₹395 crore in Q2 FY25. The board declared a first interim dividend of ₹24 per equity share (face value Re 1) for FY26.

Global earnings call context: cost inflation and Asia focus

Separately, Colgate-Palmolive’s global Q1 earnings call offered a useful lens on inputs and category strategies that can influence multinational peers. CFO Stan Sutula described a $100 million increase in costs, largely from oil-based inputs, with productivity and pricing highlighted as key offsets.

Management maintained full-year organic sales growth guidance of 1% to 4% and EPS guidance in the low to mid-single digits range, while reducing gross margin guidance for the year due to higher raw material and packaging costs. The company outlined mitigation levers including revenue growth management (RGM), pricing, premium innovation, price-pack architectures, mix improvement opportunities, and the SGPP program.

Asia Pacific and India were discussed as important growth drivers, with CEO Noel Wallace citing innovation and digital execution, alongside strong performance in China and India. The call also covered Hill’s Pet Nutrition and an exit from private label pet food, with the exit expected to be complete by Q3 and the impact tapering off by the back half of the year.

Stock check: where shares traded

Shares of Colgate-Palmolive (India) were trading at ₹2,390 on the BSE at 2:13 pm on the day referenced in the disclosure. The market reaction sits alongside the brokerage target resets and the company’s own expectation of a gradual recovery later in the year.

Key numbers at a glance

Market impact: what the numbers and notes imply

The immediate market impact is centred on slower top-line growth and profit compression, alongside concerns on competitive intensity and promotional activity. JPMorgan’s note that higher trade promotions muted price growth in Q1 is relevant because it signals a tougher pricing environment even for strong brands.

At the same time, the Q2 FY26 sequential improvement in net sales to ₹1,507 crore from ₹1,421 crore provides a datapoint that demand may be stabilising quarter-on-quarter, even as year-on-year comparisons remain pressured. Dividend declaration at ₹24 per share also signals confidence in cash generation and capital return policy, although it does not change the operating backdrop described by management.

Analysis: why the brokerage cuts matter now

Target price cuts clustered around a similar narrative: near-term growth looks muted, competitive intensity remains elevated, and recovery is expected to be back-ended. When multiple brokerages cut targets while maintaining mixed ratings, it often reflects a valuation reset rather than a single thesis change.

The divergence between Nuvama’s “Buy” stance and multiple “Sell” calls highlights that investors are debating whether current softness is cyclical (demand and base effects) or structural (category and competitive dynamics). Management’s emphasis on premium portfolio growth and brand investment suggests the company is prioritising mix and long-term positioning, but the street is looking for clearer signs of volume recovery and pricing normalisation.

Conclusion

Colgate-Palmolive (India) entered FY26 with a weaker Q1 on revenue and profit, and brokerages responded by lowering targets and trimming earnings expectations. The company continues to cite premiumisation and brand investment as core levers and expects a gradual recovery in the back half of the year. The next milestones for investors are follow-through on sequential momentum after Q2 FY26, and whether competitive and demand conditions in urban markets improve in the remainder of FY26.